US$2,000.00
May 2010
Hemophilia - Drug Pipeline Analysis and Market Forecasts to 2016
GlobalData’s pharmaceutical and healthcare report, “Hemophilia – Drug Pipeline Analysis and Market Forecasts to 2016”. The report is an essential source of information and analysis on the global hemophilia market. The report identifies the key trends shaping and driving the global hemophilia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hemophilia sector.
Order Now
|
More Information
|
Tell-a-Friend
US$3,500.00
Mar 2010
The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016
GBI Research has released its research - “The Future of Blood Disorders Therapeutics, Analysis and Market Forecasts to 2016 - Better and More Cost-Effective Treatment Options Create Opportunities”. The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global blood disorders market. The report analyzes the markets for blood disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
Order Now |
More Information |
Tell-a-Friend
US$2,224.00
Feb 2010
Statins: The World Market 2010-2025
Statins are potent cholesterol-lowering drugs, making them important in the prevention of coronary heart disease. Consequently, statins constitute one of the most important sectors of the pharmaceutical industry, with total revenues exceeding $25 billion in 2009. Our new report - Statins: The World Market 2010-2025 - provides detailed sales predictions and supporting discussions for this important pharmaceutical sector.
Order Now |
More Information |
Tell-a-Friend
US$15,200.00
Dec 2009
Antidyslipidemics Market Forecast
The antidyslipidemic market is expected to fall to $18 billion in 2018. The decline will be driven by the deep genericization of the market, further exacerbated by the patent expiry of the top antidyslipidemic, Pfizer's Lipitor, as well as by the recent negative messages from the ENHANCE, SEAS and ARBITER 6 HALTS clinical trials.
Order Now |
More Information |
Tell-a-Friend
US$15,200.00
Dec 2009
Antithrombotics Market Forecast
The antithrombotics market, comprising anticoagulant and antiplatelet sectors, has grown steadily over the 200408 period to $17 billion. However, this has little to do with a raft of recent launches: Lovenox (enoxaparin, Sanofi-Aventis), Plavix (Sanofi-Aventis and Bristol-Myer's Squibb), warfarin and aspirin collectively occupy 78% of the market by volume, and 69% by value.
Order Now |
More Information |
Tell-a-Friend
US$2,995.00
Nov 2009
Anticoagulants - A Global Market Review
The world anticoagulants market is driven by patent expiries, development of novel therapeutics, and rapidly aging population. With just two therapy classes - vitamin K antagonist and heparin injectables, dominating the market, there exist enormous opportunities and interest in developing advanced, patient friendly anticoagulants. Favorable demographic patterns, like the rapidly aging world population is expected to drive demand patterns, given the tendency of aging individuals to develop various venous and arterial complications.
Order Now |
More Information |
Tell-a-Friend
US$1,495.00
Jul 2009
Anemia - Therapy Area Pipeline Report
Life Science Analytics', Blood and Lymphatic System Anemia contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of anemia drugs by company and by stage as well as a summary of the latest news and developments in this area.
Order Now |
More Information |
Tell-a-Friend
US$1,495.00
Jul 2009
Dyslipidemia - Therapy Area Pipeline Report
Life Science Analytics', Blood and Lymphatic System Dyslipidemia contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of dyslipidemia drugs by company and by stage as well as a summary of the latest news and developments in this area.
Order Now |
More Information |
Tell-a-Friend
US$1,495.00
Jul 2009
Hemorrhage - Therapy Area Pipeline Report
Life Science Analytics', Blood and Lymphatic System Hemorrhage contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of hemorrhage drugs by company and by stage as well as a summary of the latest news and developments in this area.
Order Now |
More Information |
Tell-a-Friend
US$1,495.00
Jul 2009
Hyperlipemia - Therapy Area Pipeline Report
Life Science Analytics', Blood and Lymphatic System Hyperlipemia contains detailed information on the current drug pipeline. This report provides insight into the pipeline status of hyperlipemia drugs by company and by stage as well as a summary of the latest news and developments in this area.
Order Now |
More Information |
Tell-a-Friend
US$3,400.00
Jul 2009
Hematology Analyzer Instrumentation and Reagent Markets
Clinical hematology analyzer analysis is one of the oldest and most important sectors of clinical laboratory analysis. The hematology instrument and reagent market is centered around a group of instruments called hematology analyzers. The term clinical hematology analyzer usually refers to an automated instrument for determining the presence, number and type of cellular elements in easily collected body fluids, such as blood. However, it is not necessarily limited to these determinations. The hematology analysis always includes determination of non-cellular parameters in blood, such as hemoglobin and hematocrit. Other closely related areas of clinical interest are coagulation and flow cytometry. In fact, traditional specialization barriers, such as microbiology, hematology, blood banking, immunology and even anatomical pathology are rapidly fading both operationally and instrumentally. But for the sake of defining the subject to a reasonable size, the more traditional scope of clinical hematology analyzer will be the focus of this examination. The purpose of this TriMark Publications report is to describe the specific segments of the global clinical hematology analyzer instrumentation and reagent marketplace. The review covers those segments that are highly active in terms of innovation and growth. Specifically, this study examines the markets for small-lab, as well as highly-automated large-lab, platforms and accessory equipment, such as reagents, supplies and add-on equipment from original equipment manufacturers.
Order Now |
More Information |
Tell-a-Friend
US$3,400.00
Apr 2009
Blood Glucose Testing and Diabetes Management
There has been a dramatic increase in the incidence of diabetes
worldwide, which has been exacerbated by the growing obesity problem
across the globe. Once thought of as primarily a childhood
disease--sometimes referred to as juvenile diabetes, now mostly Type 1
diabetes--the obesity crisis linked to the adoption of a high-fat,
high-carbohydrate, high-calorie American diet has resulted in
skyrocketing rates of diabetes, particularly Type 2 diabetes, among
adults across the world. As such, the global market for blood glucose
testing products is undergoing a significant transition driven by the
advent of new analytical technologies and developments in diabetes
treatment.
Order Now |
More Information |
Tell-a-Friend
US$15,200.00
Jan 2009
Antithrombotics Market Forecast
The antithrombotic market is expected to grow to $22 billion by 2017. The growth will mainly be due to the introduction of new agents onto the market, such as prasugrel and rivaroxaban, which will offer significant improvements over the current standards of care (Plavix (clopidogrel) and warfarin, respectively).
Order Now |
More Information |
Tell-a-Friend
US$2,224.00
Apr 2008
Pharmaceutical Control of Blood Diseases Market Analysis and Forecasts Report 2008
In 2007, blood diseases cost the US's economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. From oxygen delivery to immunological defence to clotting, blood has vital physiological functions, and clear, expensive treatments. This brand new blood diseases treatments report breaks down therapies into four main groups:...
Order Now |
More Information |
Tell-a-Friend
